Featured posts

Cochlear receives FDA clearance of Baha 6 Max

Cochlear receives FDA clearance of Baha 6 Max, industry’s smallest 55 dB sound processor now with direct Android streaming Lone Tree, Colo. (March 8, 2021) — Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announces today the U.S. Food and Drug Administration (FDA) clearance of the new Cochlear™ Baha® 6 Max Sound Processor, designed to improve hearing outcomes for people […]

Read More

Cochlear™ Case Studies – Use of Slim Straight Electrode with Dr. Daniel Zeitler

By Daniel M. Zeitler, MD, FACS Cochlear Case Studies is a new series on Cochlear ProNews that highlights relevant clinical and surgical scenarios surrounding the latest hearing industry topics and research. We’re excited to partner with our professionals to highlight their experiences surrounding specific patients. The first installment will specifically feature surgeons, their cases and contributing factors for use of different electrodes. […]

Read More

Counseling new indications and the importance of early access to sound

By Ryan Lopez, Director, Nucleus® Product Management & Marketing at Cochlear Americas For 20 years, cochlear implants have been indicated in children no younger than 12 months of age. Earlier this year, Cochlear received FDA approval to lower the age of cochlear implantation from 12 months to 9 months for children with bilateral profound sensorineural hearing loss.* This important approval ensures that […]

Read More

All posts